Synairgen announced that more than 75 out of the targeted 100 hospitalised COVID-19 patients have been dosed with SNG001. Additionally, an amendment to Synairgen’s Phase II study (SG016) of SNG001 (inhaled interferon – IFNβ-1a) was granted and listed on the NHS Research Authority website on 29 April. The amendment will allow the study to start enrolling patients with SARS-CoV-2 in the home setting, within 72 hours of symptoms first developing. The aim is to be able to treat C
30 Apr 2020
Synairgen - COVID-19 trial (SG016) update
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Synairgen - COVID-19 trial (SG016) update
Synairgen plc (SNG:LON) | 5.1 0 0.0% | Mkt Cap: 10.3m
- Published:
30 Apr 2020 -
Author:
Mark Brewer | Cavendish Research -
Pages:
4
Synairgen announced that more than 75 out of the targeted 100 hospitalised COVID-19 patients have been dosed with SNG001. Additionally, an amendment to Synairgen’s Phase II study (SG016) of SNG001 (inhaled interferon – IFNβ-1a) was granted and listed on the NHS Research Authority website on 29 April. The amendment will allow the study to start enrolling patients with SARS-CoV-2 in the home setting, within 72 hours of symptoms first developing. The aim is to be able to treat C